Skip to main content
Caplight Logo









GenrAb, Inc.

GenrAb, Inc.

Private
Dallas, TexasHealthcare & Life Scienceshttps://genrab.com/

Last Round

Seed

Apr 22, 2025

Total Funding Raised

$5.6M

Company Overview

GenrAb, Inc. is a biotechnology company that develops neuroprotective therapies by harnessing the human immune system to identify fully-human monoclonal antibodies for the treatment of neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologymonoclonal antibodydrug discoverybiotechneuroprotectionantibody therapeuticsneurodegenerative diseaseAGSantibody gene signatureblood-brain barrierbiotech startupdrug pipelinetherapeutic antibodyneuroscience startupcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GenrAb, Inc. Comparables

Compare GenrAb, Inc. with similar companies based on industry and business-model similarity.

GenrAb, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alchemab Therapeutics
79%
Nura Bio
76%
Sanofi
72%

GenrAb, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 22, 2025

GenrAb, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 12, 2025

    Developing therapy to protect brain cells under stress, potentially treating MS and ALS.

  • Apr 22, 2025

    $6M round led by Actium Group

GenrAb, Inc. Filings

Explore SEC and related filing metadata, where available.

GenrAb, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GenrAb, Inc.'s valuation, stock price, and market status.

Is GenrAb, Inc. a public or private company?

GenrAb, Inc. is a private company.

What is the current stock price of GenrAb, Inc.?

GenrAb, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is GenrAb, Inc. worth (valuation)?

Valuation information for GenrAb, Inc. is not publicly available.

Can I buy GenrAb, Inc. stock?

GenrAb, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GenrAb, Inc.'s last funding round?

GenrAb, Inc.'s most recent funding round was Seed on April 22, 2025.

Who are the main investors in GenrAb, Inc.?

Key investors in GenrAb, Inc. include Actium Group.

Will GenrAb, Inc. IPO soon?

No public IPO plans have been announced for GenrAb, Inc..

How can I track GenrAb, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GenrAb, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDallas, Texas
Year Founded2022
Last FundingApr 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?